Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diltiazem + verapamil
- Development stage
- Preclinical
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two non-dihydropyridine calcium channel blockers used primarily for hypertension management. Both medications work by inhibiting calcium influx into cardiac and vascular smooth muscle cells during depolarization, resulting in vasodilation and reduced blood pressure. This combination may be considered for patients with a history of angioedema to ACE inhibitors or those at risk of hyperkalemia, though it requires careful monitoring due to potential interactions.
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)CACNA1A (P-type Calcium Channel)KCNH2 (Voltage-gated potassium channel subfamily H member 2)ADRA1A (α1A)ADRA2A (α2A)
Beyond the preview
Go deeper on diltiazem + verapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diltiazem + verapamil.